Noertersheuser P

No ORCID on file · 5 papers in corpus · active 2018-2021

Study types

  • article 3
  • review 1

Condition tags

  • endometriosis 4
2021
Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women.
Clinical and translational science ·doi:10.1111/cts.13006

Decline of bone mineral density (BMD) during menopause is related to increased risk of fractures in postmenopausal women, however, this relationship in premenopausal women has not been established. To quantify this relationship, real-world …

article 2021
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
Clinical and translational science ·doi:10.1111/cts.13040

Abstract Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consi…

review 2020
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
Clinical pharmacokinetics ·doi:10.1007/s40262-019-00840-7

The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affe…

article 2020
Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
CPT: pharmacometrics & systems pharmacology ·doi:10.1002/psp4.12560

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population expos…

article 2018
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis
Clinical pharmacokinetics ·doi:10.1007/s40262-018-0629-6

IntroductionElagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to u…